Pembrolizumab as second-line therapy for advanced urothelial carcinoma
Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).